Bio Path Net Worth
Bio Path Net Worth Breakdown | BPTH |
Bio Path Net Worth Analysis
Bio Path's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bio Path's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bio Path's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bio Path's net worth analysis. One common approach is to calculate Bio Path's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bio Path's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bio Path's net worth. This approach calculates the present value of Bio Path's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bio Path's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bio Path's net worth. This involves comparing Bio Path's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bio Path's net worth relative to its peers.
Enterprise Value |
|
To determine if Bio Path is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bio Path's net worth research are outlined below:
| Bio Path Holdings generated a negative expected return over the last 90 days | |
| Bio Path Holdings has high historical volatility and very poor performance | |
| Bio Path Holdings has some characteristics of a very speculative penny stock | |
| Bio Path Holdings has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (16.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bio Path Holdings currently holds about 17.02 M in cash with (11.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Bio-Path Holdings Inc Q3 2024 Earnings Call Highlights Strategic Advances and Financial ... |
Bio Path uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bio Path Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio Path's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bio Path's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Path is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Path Holdings backward and forwards among themselves. Bio Path's institutional investor refers to the entity that pools money to purchase Bio Path's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Global Retirement Partners, Llc. | 2024-09-30 | 4.0 | Hanson Mcclain Inc | 2024-09-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 97 K | Hrt Financial Llc | 2024-06-30 | 14.1 K | Vanguard Group Inc | 2024-09-30 | 13.5 K | Geode Capital Management, Llc | 2024-06-30 | 10.9 K | Tower Research Capital Llc | 2024-06-30 | 3.7 K | Blackrock Inc | 2024-06-30 | 2.4 K | Ubs Group Ag | 2024-06-30 | 859 | Qube Research & Technologies | 2024-06-30 | 100.0 |
Follow Bio Path's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.44 M.Market Cap |
|
Project Bio Path's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.99) | (4.74) | |
| Return On Capital Employed | (12.06) | (11.45) | |
| Return On Assets | (4.99) | (4.74) | |
| Return On Equity | (36.46) | (34.64) |
When accessing Bio Path's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bio Path's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bio Path's profitability and make more informed investment decisions.
Evaluate Bio Path's management efficiency
Bio Path Holdings has return on total asset (ROA) of (1.4003) % which means that it has lost $1.4003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6618) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Path's current Return On Tangible Assets is estimated to increase to -4.74. The Bio Path's current Return On Capital Employed is estimated to increase to -11.45. As of now, Bio Path's Net Tangible Assets are increasing as compared to previous years.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.92 | 0.88 | |
| Tangible Book Value Per Share | 0.92 | 0.88 | |
| Enterprise Value Over EBITDA | (0.22) | (0.23) | |
| Price Book Value Ratio | 10.04 | 10.54 | |
| Enterprise Value Multiple | (0.22) | (0.23) | |
| Price Fair Value | 10.04 | 10.54 | |
| Enterprise Value | 2.1 M | 2 M |
Understanding the operational decisions made by Bio Path management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Return On Equity (3.66) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Path insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Path's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Path insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bio Path time-series forecasting models is one of many Bio Path's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bio Path's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Bio Path Earnings per Share Projection vs Actual
Bio Path Corporate Management
| Michael MBA | VP Operations | Profile | |
| Alan MacKenzie | Consultant | Profile | |
| Thomas Walker | Consultant | Profile | |
| MBA Ashizawa | Development Research | Profile | |
| Peter MBA | Chairman, CoFounder | Profile | |
| Jeffery MD | Consultant | Profile | |
| Victoria Rac | Regulatory Consultant | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Path Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Path. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Path listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (8.34) | Return On Assets (1.40) | Return On Equity (3.66) |
The market value of Bio Path Holdings is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Path's value that differs from its market value or its book value, called intrinsic value, which is Bio Path's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Path's market value can be influenced by many factors that don't directly affect Bio Path's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Path's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Path is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Path's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.